homepage-top-section

The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen

Yescarta is a chimeric antigen receptor (CAR) T-cell therapy that is indicated to treat diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients whose

Under the deal terms, NeuroBo will undertake the development, regulatory and commercial works for the two therapies across the world excluding certain Asian-Pacific areas. Dong-A will be responsible

Established in January 2011, IMN is a joint research unit of the University of Bordeaux and the French National Centre of Scientific Research (CNRS). The collaboration will focus

Led by Tencent, the financing round has seen participation of new investors including Touchdown Ventures, Colorcon Ventures, Navian Investments, and University of Minnesota. Additionally, Alexandria Venture Investments, 5AM

The Ministry of Food and Drug Safety (MFDS) in Republic of Korea granted the designation to taletrectinib to treat NSCLC)in adult patients. Taletrectinib has been designed for effectively

Under the deal terms, Celregen will gain the exclusive right for the development, production, and commercialisation of CLS001 to treat bullous keratopathy in the Greater China region, including

Daxxify for injection is a neuromuscular blocking agent and an acetylcholine release inhibitor, which is indicated to temporarily improve moderate to severe glabellar lines’ appearance related to corrugator

The investigational maternal vaccine candidate, hexavalent anti capsular polysaccharide (CPS) / cross reactive material 197 glycoconjugate (GBS6) is being developed to help prevent invasive GBS in new-borns. It